Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | XPO1 | O14980 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6437304 | 0.90 | AOC3 (0.36) | AOC3CPB2S1PR3SMN1; SMN2BACE1 | |
| SCHEMBL5949847 | 0.90 | AOC3 (0.36) | AOC3CPB2S1PR3SMN1; SMN2BACE1 | |
| SCHEMBL5949849 | 0.90 | AOC3 (0.36) | AOC3CPB2S1PR3SMN1; SMN2BACE1 | |
| SCHEMBL7977761 | 0.87 | AOC3 (0.35) | AOC3CPB2S1PR3BACE1XPO1 | |
| SCHEMBL7716904 | 0.86 | AOC3 (0.36) | AOC3ADRB3CPB2S1PR3BACE1 | |
| SCHEMBL7716942 | 0.84 | AOC3 (0.38) | AOC3ADRB3S1PR3BACE1 | |
| SCHEMBL7716940 | 0.84 | AOC3 (0.38) | AOC3ADRB3S1PR3BACE1 | |
| SCHEMBL4474573 | 0.84 | ADRB3 (0.39) | AOC3ADRB3CPB2KDM4EBACE1 | |
| SCHEMBL4474577 | 0.84 | ADRB3 (0.39) | AOC3ADRB3CPB2KDM4EBACE1 | |
| SCHEMBL9267480 | 0.83 | AOC3 (0.36) | AOC3S1PR3KDM4EBACE1XPO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148887-A1 | Chemical compounds | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2006-07-06 | — | — | US | disclosed |
| US-7034053-B2 | Phenethanolamine derivatives, compositions, and their use as agonists at atypical beta-adrenoreceptors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| EP-1087943-B1 | THERAPEUTIC BIARYL DERIVATIVES | GLAXO GROUP LTD (GB) | 2005-08-17 | — | — | EP | disclosed |
| EP-1366033-B1 | CHEMICAL COMPOUNDS | GLAXO GROUP LTD (GB) | 2005-04-27 | — | — | EP | disclosed |
| US-20040106672-A1 | beta-adrenoceptor agonist for the prevention or treatment of obesity; Suitable compounds of formula (I) of the invention include:2-(3-{2R-[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]propylamino}phenyl)furan-3-carboxylic acid | B3AR THERAPEUTICS, INC. | 2004-06-03 | — | — | US | disclosed |
| EP-1366033-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002060885-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2002-08-08 | — | — | WO | disclosed |
| US-6251925-B1 | AN AGONISTS FOR HUMAN BETA-3 ADRENOCEPTOR | GLAXO WELLCOME INC. | 2001-06-26 | — | — | US | disclosed |
| WO-2001042217-A1 | BETA-3 ADRENOCEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-14 | — | — | WO | disclosed |
| EP-1087943-A1 | THERAPEUTIC BIARYL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065877-A1 | THERAPEUTIC BIARYL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-12-23 | — | — | WO | disclosed |
| WO-1998043953-A1 | NAPHTHALENESULPHONIC OR CARBOXYLIC ACIDS AND THEIR USE AS ATYPICAL BETA-ADRENOCEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106672-A1 | beta-adrenoceptor agonist for the prevention or treatment of obesity; Suitable compounds of formula (I) of the invention include:2-(3-{2R-[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]propylamino}phenyl)furan-3-carboxylic acid | ADRB3, ADRB1, ADRB2 | AOC3 233/4885ADRB3 1/4885CPB2 1613/4885 |
| US-20060148887-A1 | Chemical compounds | ADRB3, GPR119, ADRB1 | AOC3 481/4885ADRB3 1/4885CPB2 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.